Clinical Scorecard: Evaluating the Effects of Plasma-Rich Platelet Injections on Perianal Sphincter Function and Quality of Life in Rectal Cancer Patients Following Low Anterior or Intersphincteric Resection: A Prospective Cohort Analysis

At a Glance

Key Highlights

• Sphincter preservation surgery often results in fecal incontinence in about half of patients.
• Platelet-rich plasma (PRP) contains growth factors that stimulate tissue repair and has been used in regenerative treatments.
• This prospective cohort study assessed PRP injections for anal incontinence in patients with adequate sphincter muscle volume and function.

Guideline-Based Recommendations

Diagnosis

• Use Wexner Incontinence Questionnaire and SF-36 Health Survey for patient-reported outcomes.
• Perform endoanal ultrasound (EAUS) to measure sphincter muscle length, thickness, and volume.
• Conduct anorectal manometry to assess resting and squeeze pressures, sensation volumes, and rectal compliance.

Management

• Conservative treatments including diet regulation, fiber supplementation, loperamide, hydration, and biofeedback should be attempted for at least 3 months prior to PRP.
• Exclude patients with normal manometric pressures, deficient external sphincter volume (<16.1 mm length, <6.8 mm thickness, <6.3 cc volume), full-thickness sphincter tears, or altered rectal compliance.
• Prepare autologous PRP by centrifugation of patient blood and inject into perianal sphincter muscles under guidance.

Monitoring & Follow-up

• Repeat EAUS and manometry 6 months post-PRP injection to evaluate changes in sphincter morphology and function.
• Assess Wexner scores, pad use, and antidiarrheal medication consumption before and 6 months after PRP.
• Long-term follow-up (≥48 months) to evaluate sustained improvements in continence and quality of life.

Risks

• Contraindications include active infection, thrombocytopenia, severe anemia (Hb <7 g/dL), pregnancy, breastfeeding, allergy to bovine thrombin, and ongoing chemotherapy.
• Potential technical difficulty injecting PRP in patients with deficient sphincter muscle volume or full-thickness tears.

Patient & Prescribing Data

Rectal cancer patients with fecal incontinence post-LAR or ISR, preserved sphincter muscle volume and function, and no local recurrence or metastasis.

PRP injections may improve sphincter function and quality of life by promoting tissue regeneration; requires prior conservative management and careful patient selection.

Clinical Best Practices

• Ensure thorough pre-treatment evaluation including manometry and EAUS to confirm eligibility.
• Adhere to standardized PRP preparation protocols to optimize platelet concentration and growth factor content.
• Combine PRP treatment with ongoing conservative measures and monitor patient-reported outcomes longitudinally.
• Exclude patients with anatomical or functional contraindications to maximize treatment efficacy and safety.

References

• Wexner Incontinence Score and SF-36 Validation in Turkish Population
• Endoanal Ultrasound and Manometry Standards
• Platelet-Rich Plasma in Regenerative Medicine